Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11026 - 11050 of 11517 in total
Green tea leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Investigational
Matched Description: … Green tea leaf is a plant/plant extract used in some OTC (over-the-counter) products. …
Schisandra chinensis fruit is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Schisandra chinensis fruit is a plant/plant extract used in some OTC (over-the-counter) products. …
Forsythia suspensa fruit is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Forsythia suspensa fruit is a plant/plant extract used in some OTC (over-the-counter) products. …
Tremella fuciformis whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Tremella fuciformis whole is a plant/plant extract used in some OTC (over-the-counter) products. …
Moringa oleifera leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Moringa oleifera leaf is a plant/plant extract used in some OTC (over-the-counter) products. …
Camphor leaf oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Camphor leaf oil is a plant/plant extract used in some OTC (over-the-counter) products. …
PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).
Investigational
Matched Description: … PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal …
PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).
Investigational
Matched Description: … PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 …
Firtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer).
Investigational
Matched Description: … Firtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients …
Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).
Investigational
Matched Description: … Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of …
Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
Investigational
Matched Description: … Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study …
Flutriciclamide F-18 is under investigation in clinical trial NCT02350426 (A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques).
Investigational
Matched Description: … Flutriciclamide F-18 is under investigation in clinical trial NCT02350426 (A Study to Assess Inflammation …
Cenersen is under investigation in clinical trial NCT02243124 (A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)).
Investigational
Matched Description: … Cenersen is under investigation in clinical trial NCT02243124 (A Study of Aezea® (Cenersen) in Transfusion …
Valomaciclovir stearate is under investigation in clinical trial NCT00831103 (A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster).
Investigational
Matched Description: … Valomaciclovir stearate is under investigation in clinical trial NCT00831103 (A Phase 2b Trial of EPB …
Fisogatinib is under investigation in clinical trial NCT04194801 (A Phase Ib/ii Study of Fisogatinib(blu-554) in Subjects With Hepatocellular Carcinoma).
Investigational
Matched Description: … Fisogatinib is under investigation in clinical trial NCT04194801 (A Phase Ib/ii Study of Fisogatinib( …
TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage colony-stimulating factor (GM-CSF).
Investigational
Matched Description: … TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage …
DCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal vascular homing peptide tCRK.
Investigational
Matched Description: … DCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal …
VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant . This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell responses to both...
Investigational
Matched Description: … a SARS-CoV-2 antigen and dsRNA adjuvant[L30493]. ... VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses …
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Experimental
Matched Description: … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. …
KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. While effective, disease progression may occur 6 to 8 months...
Investigational
Matched Description: … KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors ( …
Investigational
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.
Investigational
Matched Description: … Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial …
Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.
Investigational
Matched Description: … Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. …
Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
Investigational
Matched Description: … Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in …
PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).
Investigational
Matched Description: … PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy …
Displaying drugs 11026 - 11050 of 11517 in total